Trial Profile
Brain Amyloidosis Is Associated with Worse Cognitive Performance in Both the Cognitively Normal and Impaired Stages – a [18f]Flutemetamol PET Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2015
Price :
$35
*
At a glance
- Drugs Flutemetamol-F-18 (Primary)
- Indications Dementia
- Focus Diagnostic use
- 19 Oct 2015 New trial record
- 23 Jul 2015 Results presented at the 2015 Alzheimer's Association International Conference.